CORDIS
EU research results

CORDIS

English EN
Innovative in-line Raman analytical sensor for new upstream cell culture monitoring and qualitycontrol

Innovative in-line Raman analytical sensor for new upstream cell culture monitoring and qualitycontrol

Objective

The main objective of the CellUp business innovation project is to develop and commercialize the new disruptive in-line analytics sensor for upstream cell culture process that the biopharmaceutical industry needs for the quality and process control during the phases of process development, scale-up and manufacturing of vaccines and antibodies for human medicines based on eukaryote cells culture.
This new bioprocess analyser will be the first industrial sensor able to perform in-line quantification of the main nutrients and metabolites during the mammalian cell culture inside the bioreactor.
Today, cell cultures in bioreactors are only monitored in real time with temperature, PH and Oxygen density sensors. The negative consequences of such a limited control are huge in terms of batch failures, time consumed at each scale-up phase and in terms of untapped production yield improvement.
Our company, with its unique integrated SWIFTS technology has the opportunity to fix the above described problem by offering a high performance miniaturized in-line Raman analyzer which can be implemented as an industrial GMP sensor.
Based on the needs expressed by several major industrial actors, the company has already developed a first product successfully evaluated and released end of 2016 under the name ProCellics.
The objective of the CellUp project is to go a step further in the integration of the Raman analyser thanks to a new configuration of our technology, called SWITS-CD. We will also develop a new “standard addition method” technology and a related software to provide an easy and robust way to implement the monitoring of the cell culture. The key to the success of this new methodology development is a cell culture activity carried internally by our company.
The total accessible market is estimated at 750 M€ for a first equipment of the 20,000 biopharma industry bioreactors, allowing the emergence of a European leader with more than 300 job creation over 10 years.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

RESOLUTION SPECTRA SYSTEMS

Address

13 Chemin Du Vieux Chene
38240 Meylan

France

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 1 969 553,75

Project information

Grant agreement ID: 779218

Status

Ongoing project

  • Start date

    1 August 2017

  • End date

    31 July 2019

Funded under:

H2020-EU.3.1.

H2020-EU.2.3.1.

  • Overall budget:

    € 1 969 553,75

  • EU contribution

    € 1 969 553,75

Coordinated by:

RESOLUTION SPECTRA SYSTEMS

France